Back to School: How biopharma can reboot drug development. Access exclusive analysis here
FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 12-0 on Thursday to recommend approval of Xenazine
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury